Last reviewed · How we verify
Skin Prick Test - Allergic subjects
At a glance
| Generic name | Skin Prick Test - Allergic subjects |
|---|---|
| Sponsor | Roxall Medicina España S.A |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects (PHASE1)
- Study of Indoor Air Pollutants and Their Impact in Children's Health and Wellbeing (NA)
- OJO-miR: microRNA Expression in Allergic Conjunctivitis.
- Study of Skin and Gut Microbiome in a Skin Condition Involving Skin Barrier Impairment and Allergic Symptoms: Netherton Syndrome
- Contribution of Nasal IgE Production to the Boost of Systemic Allergen-specific IgE Upon Nasal Allergen Contact (NA)
- Factors Determining Tolerance to Nasal Allergen Exposure With Advanced Age in a Subset of Birch Pollen Allergic Subjects
- Evaluation of an Adjusted Cutoff Value for S.P.A.T (Skin Prick Automated Test) Device in Allergic Subjects (NA)
- Inhibition of Anaphylaxis by Ibrutinib (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Skin Prick Test - Allergic subjects CI brief — competitive landscape report
- Skin Prick Test - Allergic subjects updates RSS · CI watch RSS
- Roxall Medicina España S.A portfolio CI